Cargando…

The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry

Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release...

Descripción completa

Detalles Bibliográficos
Autores principales: Amini-Bavil-Olyaee, Samad, Choi, Youn Jung, Lee, Jun Han, Shi, Mude, Huang, I-Chueh, Farzan, Michael, Jung, Jae U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646482/
https://www.ncbi.nlm.nih.gov/pubmed/23601107
http://dx.doi.org/10.1016/j.chom.2013.03.006
_version_ 1782268603069890560
author Amini-Bavil-Olyaee, Samad
Choi, Youn Jung
Lee, Jun Han
Shi, Mude
Huang, I-Chueh
Farzan, Michael
Jung, Jae U.
author_facet Amini-Bavil-Olyaee, Samad
Choi, Youn Jung
Lee, Jun Han
Shi, Mude
Huang, I-Chueh
Farzan, Michael
Jung, Jae U.
author_sort Amini-Bavil-Olyaee, Samad
collection PubMed
description Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release of virions, and alterations in endosomal cholesterol can inhibit this invasion step. We show that the antiviral effector protein interferon-inducible transmembrane protein 3 (IFITM3) interacts with VAPA and prevents its association with OSBP, thereby disrupting intracellular cholesterol homeostasis and inhibiting viral entry. By altering VAPA-OSBP function, IFITM3 induces a marked accumulation of cholesterol in multivesicular bodies and late endosomes, which inhibits the fusion of intraluminal virion-containing vesicles with endosomal membranes and thereby blocks virus release into the cytosol. Consequently, ectopic expression or depletion of the VAPA gene profoundly affects IFITM3-mediated inhibition of viral entry. Thus, IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry, further underscoring the importance of cholesterol in virus infection.
format Online
Article
Text
id pubmed-3646482
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-36464822014-04-17 The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry Amini-Bavil-Olyaee, Samad Choi, Youn Jung Lee, Jun Han Shi, Mude Huang, I-Chueh Farzan, Michael Jung, Jae U. Cell Host Microbe Article Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release of virions, and alterations in endosomal cholesterol can inhibit this invasion step. We show that the antiviral effector protein interferon-inducible transmembrane protein 3 (IFITM3) interacts with VAPA and prevents its association with OSBP, thereby disrupting intracellular cholesterol homeostasis and inhibiting viral entry. By altering VAPA-OSBP function, IFITM3 induces a marked accumulation of cholesterol in multivesicular bodies and late endosomes, which inhibits the fusion of intraluminal virion-containing vesicles with endosomal membranes and thereby blocks virus release into the cytosol. Consequently, ectopic expression or depletion of the VAPA gene profoundly affects IFITM3-mediated inhibition of viral entry. Thus, IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry, further underscoring the importance of cholesterol in virus infection. Elsevier Inc. 2013-04-17 2013-04-17 /pmc/articles/PMC3646482/ /pubmed/23601107 http://dx.doi.org/10.1016/j.chom.2013.03.006 Text en Copyright © 2013 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Amini-Bavil-Olyaee, Samad
Choi, Youn Jung
Lee, Jun Han
Shi, Mude
Huang, I-Chueh
Farzan, Michael
Jung, Jae U.
The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title_full The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title_fullStr The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title_full_unstemmed The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title_short The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
title_sort antiviral effector ifitm3 disrupts intracellular cholesterol homeostasis to block viral entry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646482/
https://www.ncbi.nlm.nih.gov/pubmed/23601107
http://dx.doi.org/10.1016/j.chom.2013.03.006
work_keys_str_mv AT aminibavilolyaeesamad theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT choiyounjung theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT leejunhan theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT shimude theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT huangichueh theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT farzanmichael theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT jungjaeu theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT aminibavilolyaeesamad antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT choiyounjung antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT leejunhan antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT shimude antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT huangichueh antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT farzanmichael antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry
AT jungjaeu antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry